Repare Therapeutics, a precision oncology company, has initiated patient dosing in the expanded phase of its TRESR clinical trial, which evaluates camonsertib monotherapy in non-small cell lung cancer (NSCLC) with ATM mutations.

Camonsertib has shown promising anti-tumor activity in ongoing trials involving patients with ATM-mutated NSCLC. The rapid expansion of the TRESR trial demonstrates the company’s commitment to addressing the significant unmet medical need among patients with this rare and aggressive form of lung cancer.

The TRESR trial is a multi-center, open-label study designed to assess the safety, efficacy, and tolerability of camonsertib as a monotherapy in NSCLC patients harboring ATR-inhibitor sensitizing mutations. The NSCLC expansion aims to enroll up to 20 patients to evaluate the effectiveness of camonsertib at a recommended Phase 2 dosage.

With limited treatment options available for advanced or recurrent NSCLC, camonsertib represents a potential oral therapy with an established safety profile. Repare Therapeutics anticipates potential data readout from the monotherapy expansion in 2025.

Repare Therapeutics employs a genome-wide CRISPR-enabled platform called SNIPRx® to discover and develop targeted cancer therapies. Their pipeline includes multiple compounds in clinical development, including lunresertib, camonsertib, RP-1664, and RP-3467, as well as other preclinical programs.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.